AF
SRNE

Amalgamated Financial’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Amalgamated Financial’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$110K Buy
+47,420
New +$148K ﹤0.01% 2112

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Amalgamated Financial's SRNE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q1 2022: 47,420 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2112 among its holdings.

235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Amalgamated Financial held 47,420 shares of Sorrento Therapeutics, Inc. worth $110K as of Q1 2022.
  • Sorrento Therapeutics, Inc. was a new Amalgamated Financial position in Q1 2022.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2112 holding.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.